Last update at 2025-07-10T18:52:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
Thu 15 May 25, 04:37 AMQ1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
Wed 14 May 25, 03:31 AMIs Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?
Fri 09 May 25, 12:48 PMSarepta Therapeutics to Present at the BofA Securities Health Care Conference
Thu 08 May 25, 08:30 PMSarepta price target lowered to $125 from $183 at Needham
Thu 08 May 25, 02:36 PMSarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Thu 08 May 25, 11:21 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -689.96300M | -418.94800M | -553.06500M | -713.88000M | -362.61000M |
Minority interest | - | - | - | - | - |
Net income | -703.48800M | -418.78000M | -554.12800M | -715.07500M | -361.91800M |
Selling general administrative | 451.42M | 282.66M | 317.88M | 284.81M | 209.98M |
Selling and marketing expenses | - | - | - | - | 2.22M |
Gross profit | 793.02M | 604.84M | 476.72M | 324.25M | 266.84M |
Reconciled depreciation | 41.86M | 38.02M | 26.91M | 30.55M | 12.24M |
Ebit | -536.20100M | -449.71000M | -564.16300M | -522.32300M | -343.62800M |
Ebitda | -473.53500M | -412.11800M | -529.27600M | -469.42400M | -342.76300M |
Depreciation and amortization | 62.67M | 37.59M | 34.89M | 52.90M | 0.86M |
Non operating income net other | - | 40.76M | 11.10M | -8.31700M | -18.98200M |
Operating income | -536.20100M | -449.71000M | -564.16300M | -522.32300M | -343.62800M |
Other operating expenses | 1469.21M | 1151.60M | 1104.26M | 903.16M | 644.66M |
Interest expense | 53.25M | 63.52M | 59.95M | 30.67M | 33.71M |
Tax provision | 13.53M | -0.16800M | 1.06M | 1.20M | -0.69200M |
Interest income | 16.49M | 0.35M | 2.97M | 7.24M | 6.81M |
Net interest income | -36.76000M | -63.17100M | -56.97700M | -23.43100M | -26.89900M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | 173.24M | - |
Other items | - | - | - | - | - |
Income tax expense | 13.53M | -0.16800M | 1.06M | 1.20M | -0.69200M |
Total revenue | 933.01M | 701.89M | 540.10M | 380.83M | 301.03M |
Total operating expenses | 1329.22M | 1054.55M | 1040.88M | 846.57M | 610.47M |
Cost of revenue | 139.99M | 97.05M | 63.38M | 56.59M | 34.19M |
Total other income expense net | -153.76200M | 30.76M | 11.10M | -191.55700M | 10.14M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -703.48800M | -418.78000M | -554.12800M | -715.07500M | -361.91800M |
Net income applicable to common shares | -703.48800M | -418.78000M | -554.12800M | -715.07500M | -361.91800M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 3264.58M | 3128.37M | 3147.97M | 2984.72M | 1822.82M |
Intangible assets | 29.62M | 7.58M | 14.24M | 13.63M | 12.50M |
Earning assets | - | - | - | - | - |
Other current assets | 140.52M | 7.72M | 6.14M | 4.07M | 5.25M |
Total liab | 2405.24M | 2743.42M | 2219.97M | 2222.96M | 1004.63M |
Total stockholder equity | 859.34M | 384.95M | 928.01M | 761.76M | 818.19M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 315.00M | 419.00M | 15.05M | 22.14M | 196.67M |
Common stock | 0.00900M | 0.00900M | 0.00900M | 0.00800M | 0.00800M |
Capital stock | 0.00900M | 0.00900M | 0.00900M | 0.00800M | 0.00800M |
Retained earnings | -4446.21300M | -3910.23600M | -3206.74800M | -2848.12900M | -2294.00100M |
Other liab | - | 521.94M | 628.84M | 734.07M | 10.25M |
Good will | - | - | - | - | - |
Other assets | 0.00000M | 286.62M | 292.95M | 295.46M | 141.92M |
Cash | 428.43M | 966.78M | 2115.87M | 1502.65M | 835.08M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 653.66M | 619.60M | 452.73M | 416.03M | 264.77M |
Current deferred revenue | 50.42M | 89.24M | 89.24M | 89.24M | - |
Net debt | 968.38M | 650.58M | -977.48100M | -429.78800M | -105.46000M |
Short term debt | 123.33M | 15.49M | 271.70M | 193.55M | - |
Short long term debt | 105.48M | - | - | - | - |
Short long term debt total | 1396.81M | 1617.36M | 1138.39M | 1072.86M | 729.62M |
Other stockholder equity | 5304.62M | 4296.84M | 4134.77M | 3609.88M | 3112.13M |
Property plant equipment | - | 244.99M | 191.16M | 190.43M | 129.62M |
Total current assets | 2579.33M | 2557.86M | 2604.10M | 2485.20M | 1468.91M |
Long term investments | 6.53M | 31.32M | 34.89M | 38.80M | 31.94M |
Net tangible assets | - | 377.37M | 913.77M | 748.13M | 805.69M |
Short term investments | 1247.82M | 1022.60M | 0.00000M | 435.92M | 289.67M |
Net receivables | 439.71M | 259.70M | 171.64M | 138.58M | 93.94M |
Long term debt | 1132.52M | 1544.29M | 1096.88M | 992.49M | 681.90M |
Inventory | 322.86M | 203.97M | 186.21M | 231.96M | 171.38M |
Accounts payable | 164.92M | 95.88M | 76.74M | 111.09M | 68.09M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 0.92M | -1.66400M | -0.02000M | 0.00300M | 0.05M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | 0.00900M | 0.00800M | 0.00800M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | -3206.74800M | -2848.12900M | -2294.00100M |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 276.41M | 286.62M | 143.28M | 12.98M | 11.80M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 685.24M | 570.50M | 543.88M | 499.52M | 353.91M |
Capital lease obligations | 158.81M | 57.58M | 41.51M | 80.37M | 47.72M |
Long term debt total | - | - | 1096.88M | 992.49M | 681.90M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -1046.88300M | 436.01M | -144.08800M | 521.99M | -305.79000M |
Change to liabilities | 58.33M | -89.24400M | 749.43M | 122.98M | 90.16M |
Total cashflows from investing activities | -1046.88300M | 495.41M | -121.72100M | 286.73M | -370.48800M |
Net borrowings | 304.17M | 304.17M | 291.11M | 244.94M | -3.48100M |
Total cash from financing activities | 232.51M | 561.57M | 682.32M | 642.55M | 530.15M |
Change to operating activities | 14.62M | 103.20M | -166.32800M | -102.09100M | -136.63800M |
Net income | -703.48800M | -418.78000M | -554.12800M | -715.07500M | -361.91800M |
Change in cash | -1139.72200M | 613.81M | 668.07M | 472.82M | -228.99800M |
Begin period cash flow | 2125.52M | 1511.71M | 843.64M | 370.83M | 599.83M |
End period cash flow | 985.80M | 2125.52M | 1511.71M | 843.64M | 370.83M |
Total cash from operating activities | -325.34600M | -443.17200M | 107.47M | -456.46300M | -388.66000M |
Issuance of capital stock | 0.00000M | 548.53M | 312.05M | 365.35M | 513.41M |
Depreciation | 41.86M | 38.02M | 26.91M | 30.55M | 12.24M |
Other cashflows from investing activities | -2.42700M | 97.89M | 104.57M | -175.63800M | -3.54100M |
Dividends paid | - | - | - | - | - |
Change to inventory | -50.78000M | -83.77200M | -60.58200M | -45.93400M | -41.84000M |
Change to account receivables | -61.63800M | -51.65000M | -10.46100M | -41.83500M | -19.57600M |
Sale purchase of stock | - | 20.80M | 396.01M | 401.95M | 563.63M |
Other cashflows from financing activities | 1025.70M | 13.04M | 370.27M | 277.20M | 283.96M |
Change to netincome | 375.75M | 31.63M | 178.05M | 273.98M | 76.58M |
Capital expenditures | 30.82M | 38.49M | 82.20M | 62.71M | 64.34M |
Change receivables | - | -51.65000M | -10.46100M | -41.83500M | -19.57600M |
Cash flows other operating | - | 130.62M | -221.75700M | 41.86M | -54.14800M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | 613.81M | 668.07M | 472.82M | -228.99800M |
Change in working capital | -39.47000M | -98.16600M | 554.06M | -66.88100M | -107.89200M |
Stock based compensation | 233.02M | 113.94M | 108.07M | 78.60M | 50.13M |
Other non cash items | 142.73M | -93.99900M | -38.08500M | 224.79M | 20.19M |
Free cash flow | -356.17000M | -481.66200M | 25.26M | -519.17600M | -453.00500M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
SRPT Sarepta Therapeutics Inc |
-0.21 1.08% | 19.16 | 261.02 | 35.21 | 9.28 | 13.43 | 9.06 | -24.8209 |
NVO Novo Nordisk A/S |
1.76 2.53% | 71.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
1.68 2.41% | 71.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
1.59 0.33% | 480.56 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
REGN Regeneron Pharmaceuticals Inc |
5.98 1.08% | 558.56 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
215 First Street, Cambridge, MA, United States, 02142
Name | Title | Year Born |
---|---|---|
Mr. Douglas S. Ingram Esq. | Pres, CEO & Director | 1963 |
Mr. Ian Michael Estepan | Exec. VP & CFO | 1976 |
Mr. William F. Ciambrone | Exec. VP of Technical Operations | 1964 |
Dr. Louise R. Rodino-Klapac Ph.D. | Exec. VP, Chief Scientific Officer and Head of R&D | 1978 |
Mr. Ryan E. Brown | Sr. VP, Gen. Counsel & Corp. Sec. | 1978 |
Bilal Arif | Sr. VP of Strategy and Operations | NA |
Mary Jenkins | Sr. Mang. of Investor Relations | NA |
Ms. Alison Nasisi | Chief People Officer & VP | NA |
Dr. Diane L. Berry | Sr. VP of Global Health Policy and Gov. & Patient Affairs | NA |
Mr. Dallan Murray | Sr. VP & Chief Customer Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.